Vanderbilt Vaccine Center

Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus. Read More

To prepare for the potential of a smallpox return, Vanderbilt researchers are isolating and studying naturally occurring antibodies from the blood of previously infected or immunized people. Read More

Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it. Read More

New discoveries will guide efforts to develop vaccines or antiviral agents for norovirus, the most common cause of infectious diarrhea. Read More

A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus. Read More

Using an antibody generated at Vanderbilt University Medical Center that neutralizes the Ebola virus, researchers at the Scripps Research Institute in La Jolla, California, have determined the structure of a “decoy” protein that may enable the virus to evade detection by the immune system. Read More

Researchers at Vanderbilt University Medical Center this month began recruiting volunteers to participate in a clinical trial aimed at decoding the human “immunome,” the genetic underpinnings of the immune system. Read More

It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks. Read More

Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat. Read More

There may be a “silver bullet” for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years. Read More

In the latest VUCast: Hear from Ebola survivors helping a Vanderbilt researcher fight the deadly virus; see the high-tech way an art exhibit is bringing VU students face to face with people across the world; and find out which country music star shot his latest video with Mr. Commodore! Watch now. Read More

Two survivors of a 2014 Ebola outbreak in Nigeria visited Vanderbilt University Medical Center last week to share their experiences and participate in a study aimed at finding ways to treat the often-fatal infection. Read More

Three Nigerian physicians who survived Ebola virus disease in July 2014 after coming in direct contact with an Ebola-infected patient will speak at Vanderbilt University Medical Center next Wednesday, Sept. 16. Read More

Vanderbilt investigators have discovered how human antibodies induced during testing of an experimental “bird flu” vaccine kill the virus. Read More

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus. Read More

In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States. Read More

With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody. Read More

Vanderbilt University researchers have received a five-year, $9 million grant from the National Institutes of Health (NIH) to design more effective flu vaccines and novel antibody therapies. Read More

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus. Read More

Vanderbilt University researchers have isolated Ebola-fighting human antibodies – the first of their kind – that could lead to a new treatment for the deadly virus. Read More